The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Percentage of Participants with Grade 2 or higher renal toxicities
Time frame: 2 Months
Full Pharmacokinetic profiles for ifosfamide and its metabolites MTD of ICE with amifostine
Time frame: 2 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.